EE200300227A - P38 kinaasiga seotud haigusseisundite ravimeetodid ja kinaasi inhibiitoritena kasulikud pürrolotriasiiniühendid - Google Patents
P38 kinaasiga seotud haigusseisundite ravimeetodid ja kinaasi inhibiitoritena kasulikud pürrolotriasiiniühendidInfo
- Publication number
- EE200300227A EE200300227A EEP200300227A EEP200300227A EE200300227A EE 200300227 A EE200300227 A EE 200300227A EE P200300227 A EEP200300227 A EE P200300227A EE P200300227 A EEP200300227 A EE P200300227A EE 200300227 A EE200300227 A EE 200300227A
- Authority
- EE
- Estonia
- Prior art keywords
- kinase
- treatment
- methods
- compounds useful
- related conditions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24987700P | 2000-11-17 | 2000-11-17 | |
| US31056101P | 2001-08-07 | 2001-08-07 | |
| PCT/US2001/049982 WO2002040486A2 (en) | 2000-11-17 | 2001-11-07 | METHODS OF TREATING p38 KINASE-ASSOCIATED CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EE200300227A true EE200300227A (et) | 2003-10-15 |
Family
ID=26940426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EEP200300227A EE200300227A (et) | 2000-11-17 | 2001-11-07 | P38 kinaasiga seotud haigusseisundite ravimeetodid ja kinaasi inhibiitoritena kasulikud pürrolotriasiiniühendid |
Country Status (32)
| Country | Link |
|---|---|
| EP (1) | EP1363910B1 (hu) |
| JP (1) | JP2004522713A (hu) |
| KR (1) | KR100847605B1 (hu) |
| CN (1) | CN1622946A (hu) |
| AR (1) | AR032637A1 (hu) |
| AT (1) | ATE318820T1 (hu) |
| AU (2) | AU3276002A (hu) |
| BG (1) | BG107750A (hu) |
| BR (1) | BR0115446A (hu) |
| CA (1) | CA2429628A1 (hu) |
| CY (1) | CY1105250T1 (hu) |
| CZ (1) | CZ20031370A3 (hu) |
| DE (1) | DE60117607T2 (hu) |
| DK (1) | DK1363910T3 (hu) |
| EE (1) | EE200300227A (hu) |
| ES (1) | ES2259051T3 (hu) |
| GE (1) | GEP20063915B (hu) |
| HK (1) | HK1057555A1 (hu) |
| HR (1) | HRP20030485A2 (hu) |
| HU (1) | HUP0303897A2 (hu) |
| IL (1) | IL155570A0 (hu) |
| IS (1) | IS6816A (hu) |
| MX (1) | MXPA03004290A (hu) |
| MY (1) | MY127066A (hu) |
| NO (1) | NO20032229L (hu) |
| NZ (1) | NZ525334A (hu) |
| PE (1) | PE20020819A1 (hu) |
| PL (1) | PL366376A1 (hu) |
| PT (1) | PT1363910E (hu) |
| SK (1) | SK5402003A3 (hu) |
| WO (1) | WO2002040486A2 (hu) |
| YU (1) | YU37903A (hu) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6867300B2 (en) | 2000-11-17 | 2005-03-15 | Bristol-Myers Squibb Company | Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors |
| DE60216281T2 (de) | 2001-06-29 | 2007-07-05 | Ab Science | Die verwendung von tyrosinkinasehemmer zur behandlung von allergischen erkrankungen |
| CA2452368A1 (en) | 2001-06-29 | 2003-01-09 | Ab Science | New potent, selective and non toxic c-kit inhibitors |
| US20040266771A1 (en) * | 2001-06-29 | 2004-12-30 | Alain Moussy | Use of tyrosine kinase inhibitors for treating bone loss |
| ATE343415T1 (de) | 2001-06-29 | 2006-11-15 | Ab Science | Die verwendung von c-kit hemmer zur behandlung von entzündlichen darmerkrankungen |
| PT1401415E (pt) | 2001-06-29 | 2006-09-29 | Ab Science | Utilizacao de derivados de n-fenil-2-pirimidino-amina para o tratamento de doencas inflamatorias |
| GB0124933D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| ATE375980T1 (de) | 2002-02-12 | 2007-11-15 | Smithkline Beecham Corp | Nicotinamide und deren verwendung als p38 inhibitoren |
| AP1822A (en) | 2002-02-14 | 2008-01-30 | Pharmacia Corp | Substituted pyridinones as modulators of P38 MAP kinase. |
| US6900208B2 (en) | 2002-03-28 | 2005-05-31 | Bristol Myers Squibb Company | Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders |
| TW200306841A (en) | 2002-04-23 | 2003-12-01 | Bristol Myers Squibb Co | Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors |
| US7388009B2 (en) | 2002-04-23 | 2008-06-17 | Bristol-Myers Squibb Company | Heteroaryl-substituted pyrrolo-triazine compounds useful as kinase inhibitors |
| AU2003231034B2 (en) | 2002-04-23 | 2009-03-05 | Bristol-Myers Squibb Company | Pyrrolo-triazine aniline compounds useful as kinase inhibitors |
| TWI272271B (en) * | 2002-07-19 | 2007-02-01 | Bristol Myers Squibb Co | Process for preparing certain pyrrolotriazine compounds |
| TWI329112B (en) | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
| EP1543009A4 (en) | 2002-08-02 | 2007-08-08 | Bristol Myers Squibb Co | Pyrrolotriazine KINASE INHIBITORS |
| TW200420565A (en) | 2002-12-13 | 2004-10-16 | Bristol Myers Squibb Co | C-6 modified indazolylpyrrolotriazines |
| RU2328499C2 (ru) * | 2003-01-09 | 2008-07-10 | Астеллас Фарма Инк. | Производные пирролопиридазина, фармацевтическая композиция, способ профилактики или лечения заболеваний, применение в качестве ингибитора фосфодиэстеразы iv, и/или продуцирования tnf |
| CA2515218A1 (en) * | 2003-02-05 | 2004-08-26 | Bristol-Myers Squibb Company | Process for preparing pyrrolotriazine kinase inhibitors |
| GB0308201D0 (en) | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
| GB0308186D0 (en) | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
| ES2332135T3 (es) | 2003-06-03 | 2010-01-27 | Novartis Ag | Inhibidores p-38 basados en heterociclo de 5 miembros. |
| EP1641764B1 (en) | 2003-06-26 | 2011-07-27 | Novartis AG | 5-membered heterocycle-based p38 kinase inhibitors |
| EP1687284B1 (en) | 2003-07-25 | 2008-10-29 | Novartis AG | p-38 KINASE INHIBITORS |
| GB0318814D0 (en) | 2003-08-11 | 2003-09-10 | Smithkline Beecham Corp | Novel compounds |
| US7419978B2 (en) | 2003-10-22 | 2008-09-02 | Bristol-Myers Squibb Company | Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors |
| US7102001B2 (en) | 2003-12-12 | 2006-09-05 | Bristol-Myers Squibb Company | Process for preparing pyrrolotriazine |
| JP2007517052A (ja) * | 2003-12-23 | 2007-06-28 | ノバルティス アクチエンゲゼルシャフト | 二環式ヘテロ環式ｐ−３８キナーゼ阻害剤 |
| US7064203B2 (en) | 2003-12-29 | 2006-06-20 | Bristol Myers Squibb Company | Di-substituted pyrrolotriazine compounds |
| MY145634A (en) | 2003-12-29 | 2012-03-15 | Bristol Myers Squibb Co | Pyrrolotriazine compounds as kinase inhibitors |
| US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| TW200538453A (en) | 2004-04-26 | 2005-12-01 | Bristol Myers Squibb Co | Bicyclic heterocycles as kinase inhibitors |
| UY28931A1 (es) * | 2004-06-03 | 2005-12-30 | Bayer Pharmaceuticals Corp | Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis |
| US7102002B2 (en) | 2004-06-16 | 2006-09-05 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US7432373B2 (en) | 2004-06-28 | 2008-10-07 | Bristol-Meyers Squibb Company | Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors |
| US7173031B2 (en) * | 2004-06-28 | 2007-02-06 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US7439246B2 (en) | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
| US7102003B2 (en) | 2004-07-01 | 2006-09-05 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds |
| US7504521B2 (en) | 2004-08-05 | 2009-03-17 | Bristol-Myers Squibb Co. | Methods for the preparation of pyrrolotriazine compounds |
| PE20060421A1 (es) | 2004-08-12 | 2006-06-01 | Bristol Myers Squibb Co | Procedimiento para preparar un compuesto de pirrolotriazina anilina como inhibidores de cinasa |
| US7151176B2 (en) | 2004-10-21 | 2006-12-19 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds |
| KR20070064350A (ko) * | 2004-10-26 | 2007-06-20 | 노파르티스 아게 | Ｃ-ｊｕｎ ｎ 말단 키나제 (ｊｎｋ) 및 ｐ-38 키나제억제제로서의 피롤로[1,2-ｄ][1,2-4]트리아진 |
| US7405213B2 (en) | 2005-07-01 | 2008-07-29 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith |
| US7402582B2 (en) | 2005-07-01 | 2008-07-22 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith |
| WO2007035428A1 (en) | 2005-09-15 | 2007-03-29 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| US7547782B2 (en) | 2005-09-30 | 2009-06-16 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| US7514435B2 (en) | 2005-11-18 | 2009-04-07 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US7348325B2 (en) | 2005-11-30 | 2008-03-25 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US8063208B2 (en) | 2006-02-16 | 2011-11-22 | Bristol-Myers Squibb Company | Crystalline forms of (3R,4R)-4-amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol |
| CN101535312B (zh) * | 2006-11-03 | 2013-04-24 | 百时美施贵宝公司 | 吡咯并三嗪激酶抑制剂 |
| US8268998B2 (en) | 2006-11-03 | 2012-09-18 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| AR074830A1 (es) | 2008-12-19 | 2011-02-16 | Cephalon Inc | Pirrolotriazinas como inhibidores de alk y jak2 |
| WO2010120963A1 (en) * | 2009-04-16 | 2010-10-21 | Bristol-Myers Squibb Company | Tablet formulation for p38 inhibitor and method |
| JP2013530951A (ja) * | 2010-05-28 | 2013-08-01 | バイオクライスト ファーマシューティカルズ， インコーポレイテッド | ヤヌスキナーゼ阻害剤としてのヘテロ環式化合物 |
| CN103012439B (zh) * | 2012-11-15 | 2015-03-11 | 沈阳药科大学 | 苯甲酰基取代的噻唑并[3,2-b]-1,2,4-三嗪衍生物及其应用 |
| WO2014143607A1 (en) * | 2013-03-11 | 2014-09-18 | Bristol-Myers Squibb Company | Pyrrolopyridazines as potassium ion channel inhibitors |
| US9050345B2 (en) * | 2013-03-11 | 2015-06-09 | Bristol-Myers Squibb Company | Pyrrolotriazines as potassium ion channel inhibitors |
| ES2616025T3 (es) * | 2013-03-11 | 2017-06-09 | Bristol-Myers Squibb Company | Pirrolotriazinas como inhibidores de canales de iones potasio |
| JP6473146B2 (ja) * | 2013-10-11 | 2019-02-20 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ピロロトリアジンキナーゼ阻害剤 |
| WO2015081783A1 (zh) * | 2013-12-06 | 2015-06-11 | 江苏奥赛康药业股份有限公司 | 吡咯并[2,1-f][1,2,4]三嗪类衍生物及其制备方法和用途 |
| WO2017151409A1 (en) | 2016-02-29 | 2017-09-08 | University Of Florida Research Foundation, Incorporated | Chemotherapeutic methods |
| DK3691620T3 (da) | 2017-10-05 | 2022-10-03 | Fulcrum Therapeutics Inc | P38-kinaseinhibitor reducerer dux4- og downstream-gen-ekspression til behandling af fshd |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
| CN108516977A (zh) * | 2018-07-10 | 2018-09-11 | 刘凤娟 | 一种用于治疗恶性肿瘤的map激酶抑制剂的合成方法 |
| CN112028892B (zh) * | 2020-07-29 | 2022-12-16 | 天津全和诚科技有限责任公司 | 4-氨基-吡咯并三嗪衍生物在制备抗肺纤维化制剂中的应用 |
| CN112094219B (zh) * | 2020-09-10 | 2022-08-05 | 广东莱佛士制药技术有限公司 | 一种制备钾离子竞争性阻滞剂中间体的方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2163399A1 (en) * | 1994-11-24 | 1996-05-25 | Katsuhiro Kawano | Triazine derivative, chymase activity inhibitor and nitric oxide production inhibitor |
| WO1999024033A1 (en) * | 1997-11-12 | 1999-05-20 | Shionogi & Co., Ltd. | Method for the treatment of disorders associated with apoptosis using n-heterocyclic glyoxylamide compounds |
| PL204437B1 (pl) * | 1999-05-21 | 2010-01-29 | Bristol Myers Squibb Co | Pochodna pirolotriazyny i jej zastosowanie oraz kompozycja farmaceutyczna i jej zastosowanie |
-
2001
- 2001-11-07 ES ES01992298T patent/ES2259051T3/es not_active Expired - Lifetime
- 2001-11-07 CN CNA018189970A patent/CN1622946A/zh active Pending
- 2001-11-07 EE EEP200300227A patent/EE200300227A/xx unknown
- 2001-11-07 YU YU37903A patent/YU37903A/sh unknown
- 2001-11-07 WO PCT/US2001/049982 patent/WO2002040486A2/en active IP Right Grant
- 2001-11-07 PL PL01366376A patent/PL366376A1/xx not_active Application Discontinuation
- 2001-11-07 AU AU3276002A patent/AU3276002A/xx active Pending
- 2001-11-07 SK SK540-2003A patent/SK5402003A3/sk unknown
- 2001-11-07 GE GE5243A patent/GEP20063915B/en unknown
- 2001-11-07 PT PT01992298T patent/PT1363910E/pt unknown
- 2001-11-07 EP EP01992298A patent/EP1363910B1/en not_active Expired - Lifetime
- 2001-11-07 AT AT01992298T patent/ATE318820T1/de not_active IP Right Cessation
- 2001-11-07 AU AU2002232760A patent/AU2002232760B2/en not_active Ceased
- 2001-11-07 CZ CZ20031370A patent/CZ20031370A3/cs unknown
- 2001-11-07 JP JP2002543494A patent/JP2004522713A/ja active Pending
- 2001-11-07 BR BR0115446-0A patent/BR0115446A/pt not_active IP Right Cessation
- 2001-11-07 KR KR1020037006661A patent/KR100847605B1/ko not_active IP Right Cessation
- 2001-11-07 NZ NZ525334A patent/NZ525334A/en unknown
- 2001-11-07 IL IL15557001A patent/IL155570A0/xx unknown
- 2001-11-07 DE DE60117607T patent/DE60117607T2/de not_active Expired - Lifetime
- 2001-11-07 MX MXPA03004290A patent/MXPA03004290A/es active IP Right Grant
- 2001-11-07 HU HU0303897A patent/HUP0303897A2/hu unknown
- 2001-11-07 CA CA002429628A patent/CA2429628A1/en not_active Abandoned
- 2001-11-07 DK DK01992298T patent/DK1363910T3/da active
- 2001-11-13 MY MYPI20015207A patent/MY127066A/en unknown
- 2001-11-16 PE PE2001001141A patent/PE20020819A1/es not_active Application Discontinuation
- 2001-11-16 AR ARP010105381A patent/AR032637A1/es unknown
-
2003
- 2003-04-21 BG BG107750A patent/BG107750A/bg unknown
- 2003-05-14 IS IS6816A patent/IS6816A/is unknown
- 2003-05-16 NO NO20032229A patent/NO20032229L/no not_active Application Discontinuation
- 2003-06-16 HR HR20030485A patent/HRP20030485A2/hr not_active Application Discontinuation
-
2004
- 2004-01-19 HK HK04100424A patent/HK1057555A1/xx not_active IP Right Cessation
-
2006
- 2006-06-01 CY CY20061100698T patent/CY1105250T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EE200300227A (et) | P38 kinaasiga seotud haigusseisundite ravimeetodid ja kinaasi inhibiitoritena kasulikud pürrolotriasiiniühendid | |
| DE69910368D1 (de) | Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung von sexualfunktionsstörungen | |
| NO20015650D0 (no) | Pyrrolotriazin-inhibitorer for kinaser | |
| ID22982A (id) | PIRAZOL-PIRAZOL TERSUBSTITUSI SEBAGAI INHIBITOR KINASE p38 | |
| DE60023268D1 (de) | INHIBITEURS PURIQUES DE KINASE 2 DEPENDANTE DES CYCLINES et IkB-alpha | |
| EE05481B1 (et) | Kinasoliini derivaadid kasvajate raviks | |
| EE200200715A (et) | Asendatud kinasoliini derivaadid ja nende kasutamine inhibiitoritena | |
| EE200100659A (et) | Diaminotiasoolid ja nende kasutamine proteiinikinaaside pärssimiseks | |
| EE200200576A (et) | Oksasooli derivaadid ja nende kasutamine türosiini kinaasi inhibiitoritena | |
| EE200100717A (et) | Indasooliühendid ja farmatseutilised kompositsioonid proteiini kinaaside inhibeerimiseks ja meetodid nende kasutamiseks | |
| AU2003224257A8 (en) | Heterocyclic compounds and their use as modulators of p38 map kinase | |
| EE200200461A (et) | Pteridiiniühendid psoriaasi raviks | |
| DE60136477D1 (de) | Retinoide zur behandlung von emphysem | |
| NO20023482D0 (no) | Fremgangsmåte for behandling av stoffmisbruk | |
| HK1077520A1 (zh) | 用作p38促細胞分裂原活化蛋白激酶抑制劑的吲哚類衍生物 | |
| ATE273276T1 (de) | Cyclobutendion-derivate zur behandlung von artherosclerose | |
| DE50105735D1 (de) | Chlorzoxazon zur behandlung von psoriasis | |
| WO2002076396A3 (en) | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases | |
| NO334788B2 (no) | Fremgangsmåte for behandling av søvnløshet | |
| EP1631145A4 (en) | P38 KINASEHEMMER COMPOSITION AND METHOD FOR THEIR USE | |
| DE60102471D1 (de) | Indolderivate zur verwendung in der behandlung von zns-störungen | |
| DE50003481D1 (de) | Verwendung von schmutzablösenden formulierungen zur behandlung von oberflächen | |
| SI1363910T1 (sl) | Postopki zdravljenja s P38 kinazo povezanih stanjin pirolotriazinske spojine, uporabne kot inhibitorji kinaze | |
| HK1062806A1 (en) | Novel methods for the treatment and prevention of pain using stress- activated protein kinase inhibitors | |
| ATE344671T1 (de) | Verwendung von enoxaparin zur behandlung der zerebralen ischämie |